Abstract
Veterans with posttraumatic stress disorder (PTSD) have poorer treatment responses than the general public, which suggests that alternative treatment approaches may be required to support veterans who do not benefit from standard evidence-based approaches. Psilocybin-assisted psychotherapy (PAP) involves administration of psilocybin in a supportive therapeutic setting. PAP has been evidenced to be safe and feasible in a range of recent studies supporting individuals with mental health difficulties including depression, obsessive compulsive disorder, and anxiety. This protocol paper outlines a study aiming to explore the safety and feasibility of PAP for veterans (n = 8) with PTSD. Participants will be offered two dosing sessions of 25 mg of psilocybin, followed by Cognitive Processing Therapy. Eligible participants are UK military veterans who meet criteria for current PTSD and who have completed thorough physical and psychological assessment. The study is subject to ethical approval by the Health Research Authority and Medicines and Healthcare products Regulatory Agency combined review.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
